eli lilly glp 1 market share is now pharma's top revenue company. It just got FDA approval for an oral GLP-1, but Wall Street isn't celebrating Betting on GLP-1 - by

Hair loss is reported by some GLP-1 users, likely related to rapid weight loss and nutritional changes rather than the medication itself

The conversion between units and milligrams varies depending on the concentration of the product being used

Standards of Medical Care in Diabetes2024

When examining a composite cardio outcomes endpoint (death from CV disease, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina), the ELIXA trial suggested that GLP-1s did not increase cardiovascular event risk (hazard ratio of 1.02)

[DOI] [PMC free article] [PubMed] [Google Scholar] 21.Srinath R., Pedersen S., Neff L., Cao D., Kao C.Y., Stefanski A., Ahmad N., Eun Lee C.J

Cautionary Note Regarding Forward-Looking Statements This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended